About Vivotecnia
Vivotecnia is a Healthcare company based in Tres Cantos (Spain) founded in 2002, and was acquired by Clave in June 2007. Preclinical contract research services are provided to biopharma firms. Vivotecnia offers products and services including Toxicology Services, Biocides Testing, Cosmetics Safety Assessment, and Medical Device Testing. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its competitors include ZeClinics and Specipig; 1 of its 2 listed competitors has raised funding.
Company details
Vivotecnia was founded in 2002 and is based in Tres Cantos, Spain. Preclinical contract research services are offered to biopharma companies, focusing on general toxicology, inhalation toxicology, genotoxicity, safety pharmacology, and efficacy studies. Animal species utilized include rats, mice, rabbits, dogs, guinea pigs, mini-pigs, and non-human primates. Operations emphasize safety and efficacy assessments in the biopharmaceutical sector.
- Headquarters Tres Cantos, Spain
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website vivotecnia.com
- Social LinkedIn X
- Acquired by Clave (Jun 2007)
- Latest Funding Round$536.8K (USD), Grant
Oct 2017
- InvestorsEuropean Union
& 2 more
- Acquired byClave
(Jun 2007)
Products & Services of Vivotecnia
Vivotecnia offers a comprehensive portfolio of products and services, including Toxicology Services, Biocides Testing, Cosmetics Safety Assessment, and Medical Device Testing.
Preclinical toxicology testing for safety and regulatory needs
Services for EU BPR-compliant biocidal product authorization
Safety tests for cosmetics and ingredients compliance
Evaluation per ISO 10993 for device safety
Funding Insights of Vivotecnia
- Total Rounds 1
- Last Round Grant — $536,799
- First Round $536,799
(Oct 2017)
- Investors Count 1
All 1 funding rounds of Vivotecnia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $536,799 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Vivotecnia
Vivotecnia has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Clave and Mobius Corporate Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Clave is engaged in venture capital investments and management. | clave.capital | Pamplona, Spain | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
| mobius.es |
Investor details for Vivotecnia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Vivotecnia
3 dated milestones of Vivotecnia across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Vivotecnia is founded.
- Exit Acquired by Clave.
- Funding First funding round of $537K.
Competitors of Vivotecnia
Vivotecnia has 2 listed competitors in our database, 1 of them funded. They include ZeClinics and Specipig.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| zeclinics.com | 2013 | Barcelona, Spain | Zebrafish models for toxicity studies are developed by ZeClinics CRO. | |||
| specipig.com | 2013 | Barcelona, Spain | $605,119 | Biomedical research services using swine models are offered by Specipig. |
Detailed competitors of Vivotecnia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vivotecnia
The website of Vivotecnia (vivotecnia.com) receives about 1.9K visits a month and ranks #8,676,376 among all websites worldwide, #7,449 in Biotechnology and Pharmaceuticals.
- Monthly visits1.9K
▲ 4.8% vs previous month
- Global rank#8,676,376
among all websites
- Category rank#7,449
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.7
- Average visit38 sec
- DevicesDesktop 33% · Mobile 67%
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vivotecnia
Complete news archive for Vivotecnia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vivotecnia
Vivotecnia was founded in 2002 and raised its 1st funding round 15 years after it was founded.
Vivotecnia is headquartered in Tres Cantos, Spain. It is registered at Tres Cantos, Madrid, Spain.
Vivotecnia was founded in 2002 and is based in Tres Cantos, Spain. Preclinical contract research services are offered to biopharma companies, focusing on general toxicology, inhalation toxicology, genotoxicity, safety pharmacology, and efficacy studies. Animal species utilized include rats, mice, rabbits, dogs, guinea pigs, mini-pigs, and non-human primates. Operations emphasize safety and efficacy assessments in the biopharmaceutical sector.
Vivotecnia offers Toxicology Services, Biocides Testing, Cosmetics Safety Assessment, and Medical Device Testing.
Vivotecnia has 3 investors. Key investors include European Union, Clave, and Mobius Corporate Venture Capital.
Yes. Vivotecnia was acquired by Clave in June 2007.